propafenone has been researched along with diclofenac in 38 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (21.05) | 29.6817 |
2010's | 17 (44.74) | 24.3611 |
2020's | 13 (34.21) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Colabufo, NA; Khlebnikov, AI; Kirpotina, LN; Lacivita, E; Leopoldo, M; Perrone, R; Quinn, MT; Schepetkin, IA; Stama, ML | 1 |
Bennis, K; Ducki, S; Lesage, F; Vivier, D | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Abou-Taleb, N; Amblard, F; Amiralaei, S; Bassit, L; Coats, SJ; Domaoal, RA; Ehteshami, M; Khalil, A; Liu, P; Mahmoud, S; McBrayer, T; Ollinger Russell, O; Sari, O; Schinazi, RF; Schutter, C; Tao, S; Whitaker, T; Zhou, L; Zhou, S | 1 |
Bertagnin, C; Desta, S; Ding, X; Fang, Z; Gao, P; Huang, B; Jia, H; Jia, R; Ju, H; Kang, D; Kong, X; Liang, X; Liu, X; Loregian, A; Lu, H; Lu, X; Ma, X; Murugan, NA; Poongavanam, V; Sun, L; Tian, Y; Xu, W; Zhan, P; Zhang, J | 1 |
Sun, J; Tong, D; Yang, D; Zhang, D; Zhang, F; Zhao, G | 1 |
Chen, B; Hu, Y; Lei, Z; Liu, K; Meng, P; Tian, Y; Wang, B; Wang, K; Yang, F | 1 |
Bertagnin, C; Ding, X; Fang, Z; Gao, P; Huang, B; Jia, H; Jia, R; Kang, D; Kong, X; Liu, X; Loregian, A; Ma, X; Murugan, NA; Poongavanam, V; Sun, Z; Tian, Y; Xu, W; Zhan, P; Zhang, J | 1 |
Amblard, F; Bassit, LC; Cho, JH; Coats, SJ; De Schutter, C; Domaoal, RA; Ehteshami, M; Jiang, Y; Kasthuri, M; Lee, S; Lin, BY; McBrayer, T; Mengshetti, S; Ollinger Russell, O; Ovadia, R; Pascual, ML; Pattassery, J; Sari, O; Schinazi, RF; Tao, S; Uher, L; Verma, K; Whitaker, T; Zhang, H; Zhou, L | 1 |
Liu, M; Liu, Y; Ran, F; Zhang, D; Zhao, G | 1 |
Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W | 1 |
Fang, F; Li, J; Lv, X; Ma, X; Qiao, T; Shen, L; Tao, Q; Zhong, G | 1 |
Cao, R; Chen, B; Lei, Z; Liu, K; Tian, Y; Wang, K; Yang, F; Zhang, K; Zhao, H; Zhao, L; Zhu, H | 1 |
Hu, LL; Lin, XH; Liu, M; Liu, WJ; Lu, W; Tang, SW; Wang, PL; Wang, W; Wang, X; Yang, JJ; Yu, WW; Zhang, HK; Zhang, Q | 1 |
Chen, CH; Cocklin, S; Dick, A; Ding, X; Gao, P; Huang, T; Lee, KH; Liu, X; Meuser, ME; Sun, L; Zalloum, WA; Zhan, P | 1 |
Chen, B; Lei, Z; Liu, K; Tian, Y; Wang, J; Wang, K; Yang, F; Zhang, H; Zhang, K; Zhao, H; Zhao, X; Zhu, H | 1 |
Chen, C; Gao, Z; Gong, P; Han, Y; Hou, Y; Huang, D; Li, L; Li, S; Li, Y; Qin, M; Sun, Y; Tian, Y; Xu, S; Zhao, Y | 1 |
Chai, X; Chen, S; Jiang, BE; Jiang, X; Liang, Q; Liu, M; Lu, W; Qiu, ZL; Sun, XB; Yang, JJ; Yi, C; Yu, LF; Zhang, HK; Zhang, Q | 1 |
Hu, B; Hu, Y; Jiang, S; Meng, P; Tian, Y; Wang, J; Wang, K; Ye, Z; Zhang, H; Zhao, H; Zhu, H | 1 |
Daelemans, D; De Clercq, E; Gao, P; Ginex, T; Huang, B; Jiang, X; Kang, D; Liu, X; Luque, FJ; Pannecouque, C; Zhan, P; Zhang, J | 1 |
Cherukupalli, S; Cocklin, S; De Clercq, E; Dick, A; Ding, X; Huang, T; Jiang, X; Kang, D; Liu, X; Meuser, ME; Pannecouque, C; Sun, L; Tao, Y; Xu, S; Zalloum, WA; Zhan, P; Zhang, X | 1 |
Cherukupalli, S; Cocklin, S; De Clercq, E; Dick, A; Ding, D; Ding, X; Gao, S; Huang, T; Jiang, X; Kang, D; Liu, X; Meuser, ME; Pannecouque, C; Sun, L; Tao, Y; Xu, S; Zalloum, WA; Zhan, P; Zhang, X | 1 |
An, R; Cao, C; Feng, YL; Guo, C; Guo, MB; Hou, Z; Wang, X; Wang, YX; Zhang, R; Zhao, XY | 1 |
Bertagnin, C; Du, R; Guizzo, L; Hou, L; Huang, B; Jia, R; Ju, H; Kang, D; Kong, X; Li, P; Liu, X; Loregian, A; Ma, X; Murugan, NA; Poongavanam, V; Zhan, P; Zhang, Y | 1 |
Fu, Y; Gong, Q; Huang, J; Huang, Y; Li, J; Li, X; Mao, F; Wang, H; Xu, Y; You, H; Zhang, D; Zhang, H; Zhu, J | 1 |
2 review(s) available for propafenone and diclofenac
Article | Year |
---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
36 other study(ies) available for propafenone and diclofenac
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Determination of log D via automated microfluidic liquid-liquid extraction.
Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.
Topics: Amides; Animals; Calcium; Chemistry Techniques, Synthetic; Drug Evaluation, Preclinical; Drug Stability; HL-60 Cells; Humans; Mice, Inbred BALB C; Microsomes, Liver; Neutrophil Activation; Rats; Receptors, Formyl Peptide; Receptors, Lipoxin; Species Specificity; Stereoisomerism | 2015 |
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
Topics: Antiviral Agents; Cells, Cultured; Dose-Response Relationship, Drug; Genotype; Hep G2 Cells; Hepacivirus; Humans; Microbial Sensitivity Tests; Molecular Structure; Prodrugs; Ribonucleotides; Structure-Activity Relationship; Viral Nonstructural Proteins; Virus Replication | 2017 |
Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
Topics: Cell Line; Drug Design; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Male; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Conformation; Safety; Viral Proteins | 2018 |
Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant.
Topics: | 2018 |
Design, synthesis, and evaluation of carboxyl-modified oseltamivir derivatives with improved lipophilicity as neuraminidase inhibitors.
Topics: Antiviral Agents; Catalytic Domain; Drug Design; Drug Stability; Enzyme Inhibitors; Humans; Hydrophobic and Hydrophilic Interactions; Influenza A Virus, H5N1 Subtype; Microsomes, Liver; Molecular Docking Simulation; Neuraminidase; Oseltamivir | 2018 |
Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
Topics: Animals; Antiviral Agents; Catalytic Domain; Dogs; Drug Design; Drug Resistance, Viral; Drug Stability; Humans; Influenza A virus; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Mutation; Neuraminidase; Nitrogen; Oseltamivir; Rats; Tissue Distribution | 2018 |
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
Topics: Animals; Antiviral Agents; Cell Line, Tumor; Deoxyribonucleosides; Deoxyuracil Nucleotides; Dogs; Drug Discovery; Enzyme Inhibitors; Hepacivirus; Humans; Male; Microsomes, Liver; Prodrugs; Viral Nonstructural Proteins | 2019 |
Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Proliferation; Drug Design; Half-Life; Humans; Lymphoma, Mantle-Cell; Microsomes, Liver; Pyrazoles; Structure-Activity Relationship | 2019 |
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells | 2019 |
Conformationally restricted quinazolone derivatives as PI3Kδ-selective inhibitors: the design, synthesis and biological evaluation.
Topics: | 2019 |
Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
Topics: Animals; Antiviral Agents; Dogs; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Molecular Structure; Neuraminidase; Oseltamivir; Structure-Activity Relationship | 2020 |
Discovery and Characterization of 1
Topics: Animals; Calcium; Cell Line, Tumor; Colonic Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Drug Discovery; Female; HEK293 Cells; Humans; Immunotherapy; Macrophages; Mice; Mice, Inbred BALB C; Microsomes, Liver; Neoplasms; RAW 264.7 Cells; Receptors, Prostaglandin E, EP4 Subtype; Structure-Activity Relationship; T-Lymphocytes, Cytotoxic; Triazoles; Tumor Microenvironment | 2020 |
Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities.
Topics: Anti-HIV Agents; Capsid Proteins; Cell Line, Tumor; Drug Design; HIV-1; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Dynamics Simulation; Molecular Structure; Phenylalanine; Protein Binding; Structure-Activity Relationship; Triazoles; Virus Replication | 2020 |
Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Microbial Sensitivity Tests; Molecular Structure; Neuraminidase; Oseltamivir; Structure-Activity Relationship; Viral Proteins | 2020 |
Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzothiazoles; Carrageenan; Cell Survival; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Epoxide Hydrolases; Hep G2 Cells; Humans; Inflammation; Ligands; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
Topics: Designer Drugs; Drug Discovery; Humans; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Structure-Activity Relationship | 2021 |
Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Humans; Hydrazines; Influenza A virus; Microbial Sensitivity Tests; Molecular Structure; Mutation; Neuraminidase; Oseltamivir; Structure-Activity Relationship; Viral Proteins | 2021 |
Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
Topics: Anti-HIV Agents; Cell Line; Drug Design; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microsomes, Liver; Molecular Dynamics Simulation; Molecular Structure; Mutation; Protein Binding; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors.
Topics: Anti-HIV Agents; Capsid Proteins; Dimerization; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Dynamics Simulation; Molecular Structure; Phenylalanine; Structure-Activity Relationship; Surface Plasmon Resonance | 2021 |
Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability.
Topics: Anti-HIV Agents; Benzothiazoles; Capsid Proteins; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Phenylalanine; Structure-Activity Relationship; Virus Replication | 2022 |
Discovery of novel aminosaccharide-based sulfonamide derivatives as potential carbonic anhydrase II inhibitors.
Topics: Amines; Animals; Carbohydrates; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Humans; Isoenzymes; Mice; Microsomes, Liver; Molecular Structure; Structure-Activity Relationship; Sulfonamides | 2021 |
Identification of C5-NH
Topics: Animals; Antiviral Agents; Biological Availability; Chick Embryo; Computer Simulation; Half-Life; Influenza A Virus, H5N1 Subtype; Mice; Molecular Docking Simulation; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Cholinesterase Inhibitors; Depression; Donepezil; Drug Design; Half-Life; Humans; Ligands; Mice; Molecular Docking Simulation; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Vilazodone Hydrochloride | 2022 |